Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

BeOne Medicines (NASDAQ:ONC) said on Wednesday that it has received approval from the U.S. FDA for a new tablet version of ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.